After CagriSema blow, Novo reveals data for obesity 'triple'

Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.

Innovent throws its hat further into China's GLP-1 ring

Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and E

Xeris’ severe low blood sugar pen gets FDA approval